enVVeno Medical (NVNO) Projected to Release Quarterly Earnings on Friday

enVVeno Medical (NASDAQ:NVNO) is expected to be announcing its results before the market opens on Friday, October 30th. Analysts expect enVVeno Medical to post earnings of ($3.27) per share and revenue of $2.25 million for the quarter.

enVVeno Medical (NASDAQ:NVNO) last released its earnings results on Thursday, July 30th. The company reported ($5.37) EPS for the quarter, missing analysts’ consensus estimates of ($4.69) by ($0.68). On average, analysts expect enVVeno Medical to post ($16.19) EPS for the current fiscal year and ($6.22) EPS for the next fiscal year.

enVVeno Medical Stock Performance

Shares of NVNO opened at $6.74 on Wednesday. enVVeno Medical has a fifty-two week low of $6.52 and a fifty-two week high of $26.25. The firm’s 50-day simple moving average is $9.19 and its two-hundred day simple moving average is $10.40.

Wall Street Analysts Forecast Growth

NVNO has been the subject of several research reports. Zacks Research raised shares of enVVeno Medical to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen upgraded enVVeno Medical to a “hold” rating in a report on Saturday. LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.